SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin surges on launching generic Kapvay tablets in US

08 Feb 2018 Evaluate

Lupin is currently trading at Rs. 814.00, up by 6.05 points or 0.75% from its previous closing of Rs. 807.95 on the BSE.

The scrip opened at Rs. 808.00 and has touched a high and low of Rs. 818.70 and Rs. 800.90 respectively. So far 140181 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1520.00 on 09-Feb-2017 and a 52 week low of Rs. 782.10 on 07-Feb-2018.

Last one week high and low of the scrip stood at Rs. 883.00 and Rs. 782.10 respectively. The current market cap of the company is Rs. 36795.22 crore.

The promoters holding in the company stood at 47.02%, while Institutions and Non-Institutions held 37.64% and 15.35% respectively.

Lupin has launched Clonidine Hydrochloride extended-release tablets, 0.1 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Kapvay tablets had annual sales of around $66 million in the US (IQVIA MAT December 2017).

Lupin's Clonidine Hydrochloride ER tablets is the generic equivalent of Concordia International Corp's Kapvay tablets. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin Share Price

2303.70 -7.20 (-0.31%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×